rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RXRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Recursion: REC-4881 End 2026 Program Update And Collaboration Candidates In Play (RXRX)

      Recursion Pharmaceuticals is maintained at a "Hold" rating. Read the latest analysis here on RXRX stock.

      Oct 15Seeking AlphaRXRX
      Recursion (RXRX) Enters New Growth Phase as Sanofi Kicks Off Drug Collab, Shares Soar
      Oct 15Yahoo FinanceRXRXSNY
      Recursion Pharmaceuticals: Sanofi News And Fundraising Sum Up Flawed Bull Thesis (RXRX)
      Oct 15Seeking AlphaRXRXSNY
      Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
      Oct 15Yahoo FinanceRXRXSNY
      What Could Go Wrong With Recursion Pharmaceuticals Stock?
      Oct 8Yahoo FinanceRXRX
      Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
      Oct 6Yahoo FinanceRXRX
      Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note

      In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.7, indicating a -1.2% shift from the previous trading day.

      Sep 28Yahoo FinanceRXRX
      Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

      RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.

      Sep 24Yahoo FinanceRXRX
      Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know

      The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.05, representing a +2.02% change from its previous close.

      Sep 22Yahoo FinanceRXRX
      Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound?

      Recursion Pharmaceuticals (RXRX) is back on traders’ screens after a sharp daily move, with the share price closing at US$3.83. Recent returns have been mixed over the past week and month. For context, Recursion Pharmaceuticals has delivered an 8.19% 1-day share price return and a 19.69% 7-day share price return, yet the total shareholder return over the past year is down 22%. This hints at short-term momentum building against a more difficult long-term backdrop and shifting views on the...

      Sep 19Yahoo FinanceRXRX
      Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know

      In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.

      Sep 16Yahoo FinanceRXRX
      Recursion Pharma CEO Najat Khan sells $78,822 in stock
      Sep 11Investing.comRXRX
      Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
      Sep 4Yahoo FinanceRXRX

      This is the newest page. Registered accounts read further back.